What is hodgkin lymphoma?
Hodgkin lymphoma usually begins in lymphocytes and commonly spreads in an orderly pattern between lymph node regions. Classical Hodgkin lymphoma contains Hodgkin and Reed–Sternberg cells in a distinctive inflammatory background and includes several histologic subtypes. Nodular lymphocyte-predominant B-cell lymphoma, the newer name for nodular lymphocyte-predominant Hodgkin lymphoma, is biologically distinct and can follow a more indolent course. Hodgkin lymphoma can occur at any age, with peaks in young adulthood and later life. Some cases are associated with Epstein–Barr virus, but infection alone does not explain most disease. Treatment planning seeks disease control while limiting heart, lung, fertility, and second-cancer risks, especially in younger patients expected to live for decades. Tissue diagnosis is essential because symptoms and scans cannot reliably separate lymphoma types. Care depends on exact pathology, early or advanced stage, bulky sites, systemic “B” symptoms, PET response, prior therapy, age, organ function, pregnancy, and personal priorities.
Signs and symptoms
The most common presentation is a painless enlarged lymph node, often in the neck, above the collarbone, underarm, or chest. Chest nodes may cause cough, pressure, shortness of breath, or discomfort. Systemic “B” symptoms include unexplained fever, drenching night sweats, and significant unintentional weight loss; their presence affects staging. Other possible features include persistent itching, fatigue, reduced appetite, abdominal fullness, or pain in involved areas. Rarely, lymph node pain follows alcohol use. Symptoms may reflect anemia, infection, or pressure on nearby structures when disease is extensive. Enlarged lymph nodes and these general symptoms are much more often caused by infection, inflammation, medicines, or other noncancer conditions. A node that persists, grows, feels firm, or accompanies unexplained systemic symptoms should be examined. Sudden breathing difficulty or chest pressure requires prompt assessment.
Diagnosis and staging
Diagnosis requires biopsy of an involved lymph node or other tissue, preferably with enough tissue for architecture and immunophenotyping. Pathology distinguishes classical Hodgkin lymphoma from nodular lymphocyte-predominant B-cell lymphoma and from non-Hodgkin lymphomas. Evaluation usually includes a history and examination, complete blood count, blood chemistry, and PET-CT or CT to map involved lymph node regions and organs. Bone marrow biopsy is used selectively because modern PET imaging often provides staging information. Hodgkin lymphoma uses an anatomic stage I–IV system, supplemented by whether systemic B symptoms are present and whether disease is bulky. Early favorable, early unfavorable, and advanced categories help shape treatment. Interim PET response can guide intensity in some protocols, but interpretation follows validated scoring systems. Fertility, heart and lung function, pregnancy status, and infection risks may be assessed before therapy. Care depends on pathology, stage, bulk, symptoms, PET response, age, and overall health.
Established treatment paths
Classical Hodgkin lymphoma is commonly treated with combination chemotherapy. The regimen and number of cycles depend on early versus advanced stage, prognostic features, and interim response. In some early-stage cases, chemotherapy is followed by involved-site radiation; response-adapted approaches may omit or add radiation to balance disease control against long-term risks. Advanced disease may use multi-agent chemotherapy or a regimen incorporating an antibody–drug conjugate or immune checkpoint inhibitor. Radiation can treat selected bulky, residual, or localized sites. Nodular lymphocyte-predominant B-cell lymphoma may be managed with observation, localized radiation, anti-CD20 antibody therapy, surgery in rare fully excised cases, or systemic therapy depending on extent and symptoms. Relapsed classical Hodgkin lymphoma may be treated with salvage therapy followed by autologous stem cell transplantation, antibody–drug conjugates, checkpoint inhibitors, radiation, or clinical trials. Treatment depends on exact subtype, stage, bulky disease, symptoms, PET response, prior therapy, age, heart and lung health, fertility considerations, and preferences. Long-term follow-up addresses recurrence and late treatment effects. Dose and radiation-field decisions should be made before therapy and revisited when response results become available.
Supportive care
Supportive care includes nausea prevention, infection assessment, blood-count monitoring, fatigue management, nutrition, activity guidance, and psychosocial support. Fertility preservation should be discussed before treatment when feasible. Regimen-specific monitoring may address lung, heart, nerve, thyroid, or immune-related effects, and radiation planning aims to limit exposure of healthy organs. Vaccination and infection-prevention advice should come from the oncology team. Palliative care can help with symptoms and quality of life during any stage of treatment. Survivorship follow-up may include screening for cardiovascular disease, thyroid dysfunction, lung problems, and second cancers based on prior treatment and age. New medicines and supplements should be reviewed for interactions, and persistent fever or breathing symptoms need timely evaluation.
Profiles documenting hodgkin lymphoma care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-09-29. The links below identify the public and clinic-provided materials used for this page.
- NCI: Hodgkin Lymphoma Treatment ↗Checked 2026-09-29
- NCI: Lymphoma—Patient Version ↗Checked 2026-09-29
How Cancer Clinic Finder compiles information · Suggest a factual correction
